PRICE INDEXES OF MENTAL HEALTH TREATMENT

价格指数是最基本的经济统计数据之一。他们寻求总结购买或生产一套特定的商品和服务以达到一定水平的福利的成本或价格。在卫生保健领域，价格指数被概念化为获得某种结果或护理质量的成本。因此，价格指数直接关系到我们如何看待卫生经济的表现。这项研究的主要目标是开发心理健康系统的价格指数衡量标准，利用管理数据，结合临床研究和临床专业知识的学习。我们的目标是衡量与预期结果水平相关的治疗支出(或价格)。这项研究建立在一系列先导性研究的基础上，这些研究考察了为重度抑郁症的急性期治疗构建价格指数的可行性。在这里描述的研究中，我们建议将试点研究扩展到：1)更广泛的抑郁症治疗(急性加持续阶段治疗)，2)精神分裂症的治疗，以及3)更广泛的环境，如有限精神健康益处的医疗保健组织和州医疗补助计划。这项工作的长期目标是制定措施，帮助政策制定者和倡导者更好地解读心理健康支出数据，并提高利用行政数据和现有临床研究评估服务于大量人口的项目绩效的能力。我们将利用三个大型数据集，其中包括八年内428,000名参保人员的大量私人参保人口，四年内36.6万名HMO和POS参保人，以及四年内超过300万名医疗补助参保人。为了评估结果，我们将使用临床文献以及三个由临床医生和研究人员组成的专家小组来评估特定消费者和治疗组合的预期结果。

Price indexes are among the most fundamental of economic statistics. They seek to summarize the cost or price of purchasing or producing a particular set of goods and services to attain a certain level of well being. In the health care area price indexes have been conceptualized as the cost of obtaining a certain outcome or quality of care. As such a price index bears directly on how we view the performance of the health economy. The principal goal of this research is to develop price index measures for mental health systems that makes use of administrative data, incorporating learning from clinical research and clinical expertise. Our aim is to measure spending (or the price) of treatments associated with an expected level of outcome. The research builds on a series of pilot studies that examined the feasibility of constructing price indexes for the acute phase treatment of major depression. In the research described here, we propose to extend pilot research to: 1) a broader view of treatment for depression (acute plus continuation phase treatment), 2) treatment of schizophrenia and 3) a wider range of settings such as an HMOs with limited mental health benefits and a state Medicaid program. The long term aim of this work is to develop measures that will help policy makers and advocates better interpret data on mental health spending and enhance the ability to assess the performance of programs serving large populations using administrative data and existing clinical research. We will draw upon three large data sets including a large privately insured population from 428,000 enrollees for eight years, 366,000 HMO and POS enrollees for four years to over 3 million Medicaid enrollees over four years. To assess outcomes we will use clinical literature along with three expert panels of clinician-researchers to rate expected outcomes for specific combinations of consumers and treatments.